SAShinya Abe

Shinya Abe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shinya Abe has a total of 105 co-authors. Here are the top co-authors by number of shared publications:

  • Hiroaki Nozawa

    Department of Surgical Oncology The University of Tokyo Tokyo Japan

    14 shared publications
  • Kazuhito Sasaki

    Department of Surgical Oncology, Graduate School of Medicine The University of Tokyo Bunkyo‐ku Tokyo Japan

    14 shared publications
  • Koji Murono

    Department of Surgical Oncology The University of Tokyo Tokyo Japan

    13 shared publications
  • Shigenobu Emoto

    Department of Surgical Oncology The University of Tokyo Tokyo Japan

    13 shared publications
  • Soichiro Ishihara

    Department of Surgical Oncology, Graduate School of Medicine The University of Tokyo Bunkyo‐ku Tokyo Japan

    13 shared publications
  • Yuzo Nagai

    Department of Surgical Oncology The University of Tokyo Tokyo Japan

    12 shared publications

Latest Publications

  • Open Access

    Sex‐Based Body Composition Changes in Patients With Rectal Cancer Undergoing Preoperative Chemoradiotherapy: A Prospective Observational Study

    by Shinya Abe, Hiroaki Nozawa, Kentaro Abe, Yumi Yokota, Shunsuke Hori, Yusuke Taguchi, Mitsutaka Yakabe, Kazuhito Sasaki, Sumito Ogawa, Soichiro Ishihara

    Introduction: Preoperative chemoradiotherapy (CRT) for rectal cancer may have an attritional impact on body composition and functional status, affecting postoperative outcomes. This prospective study characterized changes in body composition, muscle strength, and physical performance in patients with rectal cancer receiving CRT. Methods: Body composition measures by a bioelectrical impedance analysis, hand grip strength (HGS), gait speed, and the nutritional status by the Mini‐Nutritional Assessment (MNA) were assessed at Weeks 0 (pre‐CRT), 2, 4, 6, and 10 (post‐CRT). The pre‐sarcopenic status was defined as low muscle mass alone and the sarcopenic status as low muscle mass and low muscle strength or function. Results: The median age of 38 enrolled patients (25 men) was 59 years. The mean body fat mass, phase angle, and non‐dominant HGS significantly decreased by 1.3 kg, 0.3°, and 0.7 kg, respectively, after CRT. Skeletal muscle mass and the MNA slightly decreased, while gait speed did not change. Significant reductions were observed in body fat mass (2.3 kg, p = 0.04) and non‐dominant HGS (1.3 kg, p < 0.01) in women, while slight decreases were noted in men. Although no significant changes were detected in the pre‐ and post‐CRT sarcopenic status in men (4 pre‐sarcopenic patients), the numbers of pre‐sarcopenic and sarcopenic female patients increased from pre‐CRT (1 and 0) to post‐CRT (1 and 2). Conclusion: Muscle strength and body fat decreased in patients receiving CRT, particularly women. These exploratory data provide a foundation for future investigations into the clinical utility of sex‐sensitive therapeutic approaches.

  • Open Access

    Relationship Between the Product of Pre‐Treatment Neutrophil and Monocyte Counts and Clinical Outcomes in Rectal Cancer With Suspected Lateral Lymph Node Metastasis

    by Takayoshi Sasaki, Shinya Abe, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Yuzo Nagai, Yuzo Harada, Soichiro Ishihara

    Aim: A novel systemic inflammatory response marker, the neutrophil × monocyte value (NM value), has been identified as a negative predictive factor for responses to chemoradiotherapy in rectal cancer. However, the clinical implications of the NM value remain unknown. Methods: This study reviewed 352 patients with rectal cancer who received preoperative chemoradiotherapy between 2003 and 2023. The cut‐off value for the pre‐treatment NM value was established at the median. A pre‐treatment size of lateral lymph node (LLN) ≥ 8 mm was defined as clinical LLN metastasis. The prognostic significance of the NM value was evaluated. Results: The cut‐off NM value was 1 100 000; 179 patients had an NM value ≥ 1 100 000. Ninety‐nine patients had LLN ≥ 8 mm. Disease‐free survival (DFS) was significantly shorter in patients with an NM value ≥ 1 100 000 than in those with an NM value < 1 100 000. DFS and overall survival (OS) were shorter in patients with LLN ≥ 8 mm than in those with LLN < 8 mm. The LLN size and NM value were identified as independent prognostic factors for DFS (LLN size—hazard ratio (HR): 1.51, p = 0.04, NM value—HR: 1.53, p = 0.04). Patients with LLN ≥ 8 mm and an NM value ≥ 1 100 000 had the poorest prognosis among the populations compared by the combination of LLN size and NM value. Conclusions: The pre‐treatment NM value is an independent prognostic factor associated with DFS. In patients with LLN ≥ 8 mm, a high NM value may be a significant indicator of a poor prognosis.

  • Open Access

    Impact of Body Weight Loss During Preoperative Chemoradiotherapy on Prognosis of Patients With Lower Rectal Cancer

    by Shinya Abe, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Yuzo Nagai, Yuzo Harada, Takahide Shinagawa, Soichiro Ishihara

    Background: Preoperative chemoradiotherapy is the standard treatment for locally advanced rectal cancer (LARC), but may cause body composition changes. The prognostic impact of these changes remains unclear. The present study investigated the relationship between changes in body weight and composition during chemoradiotherapy, such as the psoas muscle mass index, visceral fat index, and subcutaneous fat index (SFI) obtained from computed tomography images, and long‐term outcomes in LARC patients. Methods: This retrospective study included 343 patients with LARC treated with preoperative chemoradiotherapy followed by curative resection between 2005 and 2023 at our hospital. Changes in body composition during chemoradiotherapy were retrospectively assessed, and the relationship between each index and long‐term outcomes was examined. Results: Forty‐one patients had body weight loss ≥ 10% during chemoradiotherapy, which correlated with reductions in 5‐year overall survival (OS) (68.2% vs. 90.5%, p < 0.001) and disease‐free survival (DFS) (53.5% vs. 70.9%, p = 0.005) rates. SFI loss ≥ 22.0% was also associated with a lower 5‐year OS rate (74.3% vs. 88.3%, p < 0.001). A multivariate analysis identified body weight loss ≥ 10% (HR 2.98, p = 0.001) and SFI loss ≥ 22.0% (HR 2.84, p = 0.007) as independent predictors of worse OS. Body weight loss ≥ 10% was also independently associated with worse DFS (HR 1.79, p = 0.014). Pre‐chemoradiotherapy body mass index ≥ 25 kg/m 2 and the cT4 factor had high odds ratios for body weight loss ≥ 10% during chemoradiotherapy. Conclusion: Body weight loss during preoperative chemoradiotherapy is an independent predictor of worse OS and DFS in LARC.


  • Primary tumor location is a risk factor for postoperative development of sarcopenia as a predictive marker for unfavorable outcomes in patients with colorectal cancer

    by Shinya Abe, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Hiroyuki Matsuzaki, Yuzo Nagai, Takahide Shinagawa, Hirofumi Sonoda, et al.

    Background The impact of the skeletal muscle volume after colorectal cancer surgery is unclear. Thus, we investigated the change of skeletal muscle mass after surgery and its effects on long-term outcomes. Methods This retrospective analysis included clinical stage I-IV colorectal cancer patients who underwent curative resection between April 2012 and March 2014 in our hospital. The psoas muscle area at the third lumbar vertebra level was evaluated by computed tomography and was divided by the square of height to obtain the psoas muscle mass index (PMI). Sarcopenia was defined using the PMI cut-off values for Asian adults of 6.36 cm2/m2 for males and 3.92 cm2/m2 for females. Results Among eligible 354 patients, 166 and 145 had pre- and postoperative sarcopenia one year after surgery, respectively. Five-year disease-free survival (DFS) and overall survival (OS) rates were 81.7% and 94.5%, respectively. In multivariate analysis, postoperative sarcopenia was an independent risk factor for shorter DFS [hazard ratio (HR) 1.71, p = 0.0171] and OS (HR 2.42, p = 0.0455), respectively, but preoperative sarcopenia was not a prognosticactor for either. One year after colorectal resection, 24 patients (6.8%) were newly diagnosed with sarcopenia, while 45 (12.7%) recovered from sarcopenia. Rectal cancer was identified as an independent risk factor for the postoperative development of sarcopenia (odds ratio 3.12, p = 0.0440). Conclusion Postoperative sarcopenia one year after surgery was associated with poor DFS and OS. Thus, clinicians need to consider skeletal muscle loss during postoperative surveillance, particularly in rectal cancer patients without sarcopenia before surgery.


  • Open Access

    Preoperative sarcopenia negatively impacts short‐ and long‐term outcomes of rectal cancer: A propensity score‐matched analysis

    by Shinya Abe, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Kensuke Kaneko, Yuichiro Yokoyama, Hiroyuki Matsuzaki, Yuzo Nagai, Soichiro Ishihara

    Aim: Sarcopenia is associated with poor postoperative outcomes in various cancers; however, limited evidence is available for rectal cancer. Therefore, the present study examined the effects of skeletal muscle mass on the short‐ and long‐term outcomes of rectal cancer.Materials and Methods: A total of 787 Stage I–IV rectal cancer patients who underwent curative resection between 2003 and 2021 at The University of Tokyo Hospital were included. We conducted a propensity score‐matched analysis to mitigate confounding bias. The third lumber psoas muscle mass was measured to define sarcopenia.Results: Among 787 patients, 350 (44.5%) were classified as having sarcopenia. After matching, 532 patients were analyzed. Patient characteristics in the sarcopenia and nonsarcopenia groups were similar; however, the body mass index differed. The sarcopenia group had significantly higher rates of postoperative complications of all grades (33.1% vs 24.8%; p = 0.035), of grade ≥2 (29.3% vs 21.8%; p = 0.047), and anastomotic leakage (1.9% vs 0%; p = 0.0082) than the nonsarcopenia group. The 5‐y overall survival rate was significantly lower in the sarcopenia group than in the nonsarcopenia group (85.3% vs 91.8%, p = 0.019). Disease‐free survival was similar between the groups (p = 0.40). In the total cohort analysis, sarcopenia was an independent risk factor for total postoperative complications (odds ratio 1.41, p = 0.042).Conclusion: Preoperative sarcopenia is associated with more total postoperative complications, more anastomotic leakage, and worse survival in rectal cancer patients.


  • Open Access

    Neuroendocrine carcinoma associated with chronic ulcerative colitis: a case report and review of the literature

    by Yumi Yokota, Hiroyuki Anzai, Yuzo Nagai, Hirofumi Sonoda, Takahide Shinagawa, Yuichiro Yoshioka, Shinya Abe, Yuichiro Yokoyama, Hiroyuki Matsuzaki, Shigenobu Emoto, et al.

    Adenocarcinoma is a common histological type of ulcerative colitis-associated cancer (UCAC), whereas neuroendocrine carcinoma (NEC) is extremely rare. UCAC is generally diagnosed at an advanced stage, even with regular surveillance colonoscopy. A 41-year-old man with a 17-year history of UC began receiving surveillance colonoscopy at the age of 37 years; 2 years later, dysplasia was detected in the sigmoid colon, and he underwent colonoscopy every 3 to 6 months. Approximately 1.5 years thereafter, a flat adenocarcinoma lesion occurred in the rectum. Flat lesions with high-grade dysplasia were found in the sigmoid colon and surrounding area. The patient underwent laparoscopic total proctocolectomy and ileal pouch-anal anastomosis with ileostomy. Adenocarcinoma was diagnosed in the sigmoid colon and NEC in the rectum. One year postoperation, recurrence or metastasis was not evident. Regular surveillance colonoscopy is important in patients with long-term UC. A histological examination of UCAC might demonstrate NEC.


  • Open Access

    Nutritional Status Indicators Predict Tolerability to Adjuvant Chemotherapy in Patients with Stage II/III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy

    by Shinya Abe, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Hiroyuki Matsuzaki, Yuzo Nagai, Takahide Shinagawa, Hirofumi Sonoda, et al.

    Introduction: Adjuvant chemotherapy (AC) after radical surgery following preoperative chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC) is now the standard of care. The identification of risk factors for the discontinuation of AC is important for further improvements in survival. We herein examined the prognostic impact of chemotherapy compliance and its relationship with the prognostic nutritional index (PNI) before surgery. Methods: A total of 335 stage II–III LARC patients who underwent preoperative CRT between 2003 and 2022 at the University of Tokyo Hospital were retrospectively reviewed. We excluded patients with recurrence during AC and those who had not received AC. The relationship between AC and long-term outcomes and that between PNI values and the duration of AC were examined. Results: Thirty-one patients discontinued AC and 62 continued AC. Recurrence-free survival (RFS) was significantly shorter in patients who discontinued AC (p = 0.0056). The discontinuation of AC was identified as an independent risk factor for RFS (hazard ratio [HR]: 2.24, p = 0.0233). Twenty-one patients were classified as having low PNI (less than 40), which correlated with an older age, low body mass index, and incomplete AC. Low PNI was an independent risk factor for a shorter duration of AC (HR: 2.53, p = 0.0123). Conclusion: The discontinuation of AC was related to poor RFS in patients with LARC undergoing preoperative CRT. Furthermore, a low PNI value was identified as a risk factor for a shorter duration of AC.


  • Open Access

    Minimally invasive versus open multivisceral resection for rectal cancer clinically invading adjacent organs: a propensity score-matched analysis

    by Shinya Abe, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Hiroyuki Matsuzaki, Yuzo Nagai, Takahide Shinagawa, Hirofumi Sonoda, et al.

    Background: Minimally invasive surgery (MIS), such as laparoscopic and robotic surgery for rectal cancer, is performed worldwide. However, limited information is available on the advantages of MIS over open surgery for multivisceral resection for cases clinically invading adjacent organs. Patients and methods: This was a retrospective propensity score-matching study of consecutive clinical T4b rectal cancer patients who underwent curative intent surgery between 2006 and 2021 at the University of Tokyo Hospital. Results: Sixty-nine patients who underwent multivisceral resection were analyzed. Thirty-three patients underwent MIS (the MIS group), while 36 underwent open surgery (the open group). Twenty-three patients were matched to each group. Conversion was required in 2 patients who underwent MIS (8.7%). R0 resection was achieved in 87.0% and 91.3% of patients in the MIS and open groups, respectively. The MIS group had significantly less blood loss (170 vs. 1130 mL; p < 0.0001), fewer Clavien–Dindo grade ≥ 2 postoperative complications (30.4% vs. 65.2%; p = 0.0170), and a shorter postoperative hospital stay (20 vs. 26 days; p = 0.0269) than the open group. The 3-year cancer-specific survival rate, relapse-free survival rate, and cumulative incidence of local recurrence were 75.7, 35.9, and 13.9%, respectively, in the MIS group and 84.5, 45.4, and 27.1%, respectively, in the open group, which were not significantly different (p = 0.8462, 0.4344, and 0.2976, respectively). Conclusion: MIS had several short-term advantages over open surgery, such as lower complication rates, faster recovery, and a shorter hospital stay, in rectal cancer patients who underwent multivisceral resection. Graphical


  • Open Access

    Essential anatomy for lateral lymph node dissection

    by Yuichiro Yokoyama, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Hiroyuki Matsuzaki, Shinya Abe, Yuzo Nagai, Yuichiro Yoshioka, Takahide Shinagawa, et al.

    In Western countries, the gold-standard therapeutic strategy for rectal cancer is preoperative chemoradiotherapy (CRT) following total mesorectal excision (TME), without lateral lymph node dissection (LLND). However, preoperative CRT has recently been reported to be insufficient to control lateral lymph node recurrence in cases of enlarged lateral lymph nodes before CRT, and LLND is considered necessary in such cases. We performed a literature review on aspects of pelvic anatomy associated with rectal surgery and LLND, and then combined this information with our experience and knowledge of pelvic anatomy. In this review, drawing upon research using a 3-dimensional anatomical model and actual operative views, we aimed to clarify the essential anatomy for LLND. The LLND procedure was developed in Asian countries and can now be safely performed in terms of functional preservation. Nonetheless, the longer operative time, hemorrhage, and higher complication rates with TME accompanied by LLND than with TME alone indicate that LLND is still a challenging procedure. Laparoscopic or robotic LLND has been shown to be useful and is widely performed; however, without a sufficient understanding of anatomical landmarks, misrecognition of vessels and nerves often occurs. To perform safe and accurate LLND, understanding the landmarks of LLND is essential.


  • Open Access

    Primary tumor location is a risk factor for postoperative development of sarcopenia related to poor outcomes in patients with colorectal cancer

    by Shinya Abe, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Hiroyuki Matsuzaki, Yuzo Nagai, Takahide Shinagawa, Hirofumi Sonoda, et al.

    Background The present study aimed to investigate the loss of skeletal muscle mass after surgery and how it affects long-term outcomes. Methods This retrospective analysis included clinical stage I- IV colorectal cancer patients who underwent curative resection between April 2012 and March 2014 at the University of Tokyo Hospital. We excluded patients with recurrence within 12 months of colorectal resection. The psoas muscle area at the third lumbar vertebra level was evaluated by computed tomography and was divided by the square of height to obtain the psoas muscle mass index (PMI). Sarcopenia was defined using the generally accepted PMI cut-off values for Asian adults of 6.36 cm2/m2 for males and 3.92 cm2/m2 for females. Results Among 511 enrolled patients, 359 were analyzed and 169 had preoperative sarcopenia. One year after colorectal resection, 24 patients (12.6%) had newly diagnosed sarcopenia, while 46 (27.2%) had recovered from sarcopenia. Rectal cancer was identified as an independent risk factor for the postoperative development of sarcopenia (OR 5.05; 95%CI 0.08–0.48; p = 0.0003). The median follow-up period was 7.0 years, and 5-year OS and DFS rates were 94.3 and 80.4%, respectively. Postoperative sarcopenia was an independent risk factor for shorter DFS in a multivariate analysis (HR 1.62; 95%CI 1.06–2.49; p = 0.0267). Conclusion Postoperative sarcopenia one year after surgery was associated with poor DFS, and, thus, the prevention of skeletal muscle loss needs to be considered during postoperative surveillance, particularly in rectal cancer patients without sarcopenia before surgery.